Mural Oncology (MURA) Competitors

Fate Therapeutics (NASDAQ:FATE) and Mural Oncology (NASDAQ:MURA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, community ranking, dividends, valuation and analyst recommendations.

Which has higher earnings and valuation, FATE or MURA?

Fate Therapeutics has higher revenue and earnings than Mural Oncology. Fate Therapeutics is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$13.34M	12.03	-$160.93M	-$1.49	-0.94
Mural Oncology	N/A	N/A	-$207.45M	-$7.67	-0.33

Does the media prefer FATE or MURA?

In the previous week, Fate Therapeutics had 8 more articles in the media than Mural Oncology. MarketBeat recorded 11 mentions for Fate Therapeutics and 3 mentions for Mural Oncology. Mural Oncology's average media sentiment score of 0.96 beat Fate Therapeutics' score of 0.86 indicating that Mural Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mural Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate FATE or MURA?

Fate Therapeutics presently has a consensus price target of $4.14, suggesting a potential upside of 195.92%. Mural Oncology has a consensus price target of $13.00, suggesting a potential upside of 413.83%. Given Mural Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Mural Oncology is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	0 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.22
Mural Oncology	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Does the MarketBeat Community favor FATE or MURA?

Fate Therapeutics received 473 more outperform votes than Mural Oncology when rated by MarketBeat users. However, 80.00% of users gave Mural Oncology an outperform vote while only 67.18% of users gave Fate Therapeutics an outperform vote.

Company	Underperform	Outperform
Fate Therapeutics	Outperform Votes 481 67.18%	Underperform Votes 235 32.82%
Mural Oncology	Outperform Votes 8 80.00%	Underperform Votes 2 20.00%

Is FATE or MURA more profitable?

Mural Oncology has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,325.43%. Fate Therapeutics' return on equity of -45.88% beat Mural Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-1,325.43%	-45.88%	-33.95%
Mural Oncology	N/A	-70.10%	-61.30%

Which has more risk and volatility, FATE or MURA?

Fate Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500. Comparatively, Mural Oncology has a beta of 3.36, suggesting that its share price is 236% more volatile than the S&P 500.

Do insiders and institutionals hold more shares of FATE or MURA?

97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 80.2% of Mural Oncology shares are owned by institutional investors. 5.5% of Fate Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Mural Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Fate Therapeutics beats Mural Oncology on 9 of the 17 factors compared between the two stocks.